Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole
- Conditions
- Interventions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 41
- Registration Number
- NCT01913379
- Locations
- 🇫🇷
SGS, Paris, France
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT01900028
- Locations
- 🇩🇰
Research site, Herlev, Denmark
🇬🇧Research Site, Sutton, United Kingdom
An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT01823289
A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01814709
Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 51
- Registration Number
- NCT01795937
- Locations
- 🇩🇪
1220.61.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT01787331
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01772290
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01772563
- Locations
- 🇭🇺
National Institute of Oncology, Budapest, Hungary
🇭🇺PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit, Budapest, Hungary
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 80
- Registration Number
- NCT01768663
A Study of Empirical Antifungal Therapy With Itraconazole
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 138
- Registration Number
- NCT01706562
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.